- Home
- PIM vs MIST Comparison
PIM vs MIST Comparison
Compare PIM & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PIM | MIST |
|---|---|---|
| Founded | 1988 | 2003 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 153.2M | 146.9M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | PIM | MIST |
|---|---|---|
| Price | $3.00 | $0.76 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $5.86 |
| AVG Volume (30 Days) | 90.0K | ★ 1.4M |
| Earning Date | 01-01-0001 | 11-11-2026 |
| Dividend Yield | ★ 8.28% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.05 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $147.62 |
| Revenue Next Year | N/A | $476.43 |
| P/E Ratio | $59.90 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.97 | $0.75 |
| 52 Week High | $3.43 | $3.06 |
Technical Indicators
Market Signals| Indicator | PIM | MIST |
|---|---|---|
| Relative Strength Index (RSI) | 38.87 | 29.43 |
| Support Level | $2.98 | $0.75 |
| Resistance Level | $3.21 | $1.42 |
| Average True Range (ATR) | 0.04 | 0.06 |
| MACD | -0.00 | -0.00 |
| Stochastic Oscillator | 25.00 | 15.77 |
Price Performance
Historical ComparisonAbout PIM Putnam Master Intermediate Income Trust
Putnam Master Intermediate Income Trust is a closed-end fund. Its investment objective is to provide high current income and relative stability of net asset value. The fund pursues its goal by investing in U.S. high-grade, high-yield, and international fixed-income securities with limited maturities. The fund's portfolio includes the United States Government and agency mortgage obligations; mortgage-backed securities; corporate bonds and notes, and foreign government and agency bonds and notes.
About MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of cardiovascular medicines. Its approved product CARDAMYST (etripamil) nasal spray is available in the United States and is the self-administered treatment for use by patients anywhere, anytime an attack of PSVT occurs. It operates in single segment.